Format

Send to

Choose Destination
J Gen Physiol. 2014 Dec;144(6):503-12. doi: 10.1085/jgp.201411287.

Stargazin promotes closure of the AMPA receptor ligand-binding domain.

Author information

1
Department of Biochemistry and Molecular Biology, Center for Membrane Biology, University of Texas Health Science Center, Houston, TX 77030.
2
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06530.
3
Department of Biochemistry and Molecular Biology, Center for Membrane Biology, University of Texas Health Science Center, Houston, TX 77030 vasanthi.jayaraman@uth.tmc.edu.

Abstract

Transmembrane AMPA receptor (AMPAR) regulatory proteins (TARPs) markedly enhance AMPAR function, altering ligand efficacy and receptor gating kinetics and thereby shaping the postsynaptic response. The structural mechanism underlying TARP effects on gating, however, is unknown. Here we find that the prototypical member of the TARP family, stargazin or γ-2, rescues gating deficits in AMPARs carrying mutations that destabilize the closed-cleft states of the ligand-binding domain (LBD), suggesting that stargazin reverses the effects of these mutations and likely stabilizes closed LBD states. Furthermore, stargazin promotes a more closed conformation of the LBD, as indicated by reduced accessibility to the large antagonist NBQX. Consistent with the functional studies, luminescence resonance energy transfer experiments directly demonstrate that the AMPAR LBD is on average more closed in the presence of stargazin, in both the apo and agonist-bound states. The additional cleft closure and/or stabilization of the more closed-cleft states of the LBD is expected to translate to higher agonist efficacy and could contribute to the structural mechanism for stargazin modulation of AMPAR function.

PMID:
25422502
PMCID:
PMC4242809
DOI:
10.1085/jgp.201411287
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center